

PRODUCT INFORMATION




Evacetrapib

Item No. 23670

CAS Registry No.: 1186486-62-3
Formal Name: *trans*-4-[[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

MF: C₃₁H₃₆F₆N₆O₂
FW: 638.7
Purity: ≥98%
UV/Vis.: λ_{max}: 266 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Evacetrapib is supplied as a crystalline solid. A stock solution may be made by dissolving the evacetrapib in the solvent of choice, which should be purged with an inert gas. Evacetrapib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of evacetrapib in these solvents is approximately 30 mg/ml.

Description

Evacetrapib is a benzazepine inhibitor of cholesteryl ester transfer protein (CETP; IC₅₀s = 5.5 and 26 nM for human recombinant and plasma-derived proteins, respectively).¹ It is selective for CETP over a panel of cell surface and nuclear receptors with no significant inhibition at 1 μM. Evacetrapib (1-10 μM) reduces expression of the serine protease proprotein convertase subtilisin kexin 9 (PCSK9) and the LDL receptor (LDLR) in HepG2 cells in a dose-dependent manner with no effect on cell viability.² It also reduces protein levels of LDLR, SREBF2-M, and PCSK9 in HepG2 lysates, nuclear extracts, and culture medium, respectively, in a dose-dependent manner. Oral administration of evacetrapib (30 mg/kg) inhibits CETP activity by 98.5, 98.6, and 18.4% after four, eight, and 24 hours, respectively, in serum from transgenic mice expressing human CETP and ApoA1.¹ Evacetrapib increases HDL cholesterol levels in CETP/ApoA1 transgenic mice in a dose-dependent manner, including by 129.7% eight hours following administration of a 30 mg/kg dose.

References

1. Cao, G., Beyer, T.P., Zhang, Y., *et al.* Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. *J. Lipid Res.* **52(12)**, 2169-2176 (2011).
2. Dong, B., Singh, A.B., Kan, C.F.K., *et al.* CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression *in vitro* and *in vivo* through a SREBP2 dependent mechanism. *Atherosclerosis* **235(2)**, 449-462 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/03/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM